Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... a meter in size, are around us every day. ... as in some innovative early cancer treatments, but they ... traffic emissions, cosmetics, sunscreen and electronics. , A team ... by Lan Yang, PhD, the Das Family Career Development ... collaborators at Tsinghua University in China have developed a ...
(Date:9/2/2014)... September 02, 2014 Press attending the ... to take advantage of the people and events in ... below are available throughout the day. Additionally, we will ... POET and DSM representatives as well as representatives from ... is appreciated. , Please remember to RSVP to ...
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... advanced tools after their brains evolved a greater capacity for ... it took early humans almost two million years to move ... used computer modelling and tiny sensors embedded in gloves to ... order to make two types of tools during the Lower ...
... 2010Scientists at the U.S. Department of Energy,s Los Alamos ... thin films capable of absorbing light and generating electric ... in the journal Chemistry of Materials, could ... "Potentially, with future refinement of this technology, windows in ...
... Colo., Nov. 3, 2010 Bolder BioTechnology, Inc. today ... $1.2 million in Qualifying Therapeutic Discovery Project Grants.  Grants ... Discovery Project Tax Credit Program, which authorized up to ... companies with 250 or fewer employees.   ...
Cached Biology Technology:Stone Age humans needed more brain power to make big leap in tool design 2Scientists produce transparent, light-harvesting material 2Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... British Columbia researchers are part of an international team ... a step they hope will lead to a universal ... conservation efforts. Barcodes based on portions of DNA ... have already emerged as a viable solution for ...
... The most comprehensive analysis yet of the genome of childhood ... the genetic blueprint, suggesting the cancer arises from just a ... Children,s Research Hospital. The research appears in the July 27 ... of Sciences . "Our data raise the ...
... BOSTONThe androgen receptor a protein ignition switch ... a master of adaptability. When drug therapy deprives the ... receptor manages to find an alternate growth route. A ... University scientists demonstrates how. The shift from androgen-dependent to ...
Cached Biology News:UBC researchers help push for standard DNA barcodes for plants 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 3Study reveals a reprogrammed role for the androgen receptor 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: